Why Upgrade to CRT-P?
His pacemaker is being upgraded to CRT-P because he has heart failure with reduced ejection fraction (LVEF ≤35%), a high burden of right ventricular pacing, and persistent severe symptoms (NYHA class III or ambulatory IV) despite optimal medical therapy. 1
The Core Problem: Pacing-Induced Deterioration
Right ventricular pacing, particularly from the apex, causes ventricular dyssynchrony that can worsen or cause heart failure. When patients require frequent or permanent ventricular pacing and develop or have pre-existing left ventricular dysfunction, the conventional pacemaker becomes part of the problem rather than just the solution to their bradycardia.
Class I Indication for Upgrade
According to ESC guidelines, CRT upgrade from a conventional pacemaker is a Class I (strongest) recommendation with Level B evidence for patients meeting ALL of these criteria 1:
- LVEF <35%
- High percentage of ventricular pacing (typically ≥40% burden)
- NYHA class III or ambulatory class IV symptoms
- Despite adequate medical treatment
This is not a "maybe" situation—when these criteria are met, upgrade is indicated, not just considered.
The Evidence Supporting Upgrade
Randomized Controlled Trials
Four small randomized crossover trials consistently demonstrated that upgrading to CRT versus continuing RV pacing resulted in 1:
- Clinical improvement: 18% reduction in NYHA class
- Functional improvement: 22% improvement in quality of life scores
- Cardiac remodeling: 6% reduction in end-systolic diameter, 17% improvement in ejection fraction
- Fewer hospitalizations: 81% reduction in some studies
Observational Data
Seven observational studies with 188 patients showed even more dramatic improvements post-upgrade 1:
- 28% improvement in ejection fraction
- 31% reduction in NYHA class
- 43% improvement in quality of life
- 84% clinical responder rate in one study
Recent Real-World Evidence
Contemporary studies confirm these benefits persist in routine practice 2, 3, 4:
- 91.9% of patients with severe LV dysfunction improved to LVEF >35% after upgrade 3
- 35% normalized their LVEF to >50% 3
- Mean LVEF improvement of 14-15 percentage points 2, 4
- Sustained improvement over 12 months 5
What Happens Without Upgrade?
Continuing conventional RV pacing in this setting perpetuates ventricular dyssynchrony, leading to:
- Progressive LV remodeling and enlargement
- Worsening heart failure symptoms
- Increased hospitalizations
- Potential mortality impact (though CRT-P vs medical therapy mortality benefit was only marginally significant in COMPANION trial) 1
Key Predictors of Success
Patients most likely to benefit from upgrade have 5:
- ≥40% RV pacing burden (9.3% LVEF improvement vs 4.0% with <40% pacing)
- Non-ischemic cardiomyopathy (8.4% vs 4.8% improvement compared to ischemic)
- Sinus rhythm (8.4% vs 4.2% improvement compared to atrial fibrillation)
Important Caveats
Timing Matters
- Do not upgrade during acute decompensated heart failure 1
- Optimize medical therapy first and reassess as outpatient after stabilization
- This allows proper assessment of whether symptoms are truly refractory
Realistic Expectations
The upgrade procedure carries 1:
- Higher complication rates than initial implantation (more complex system)
- Shorter device longevity (CRT devices consume more battery)
- Need for venoplasty in ~23% of cases 3
- Overall complication rate remains acceptable at 1.8-11% 4, 1
The Alternative: De Novo CRT
If this were a new pacemaker indication rather than an upgrade, CRT should be considered (Class IIa) in heart failure patients with reduced EF who are expected to require high percentage ventricular pacing 1. The upgrade indication is actually stronger (Class I) because it addresses documented harm from existing RV pacing.
Bottom Line
The upgrade is happening because continuing conventional RV pacing in the setting of heart failure with reduced ejection fraction and high pacing burden is harmful, and CRT upgrade has proven benefit for symptoms, cardiac function, and hospitalizations in this exact clinical scenario.